- Bruton's tyrosine kinase inhibitors and their current status in the treatment of chronic lymphocytic leukemia2023 | First Faculty of Medicine
- Bruton's Tyrosine Kinase Inhibitors Ibrutinib and Acalabrutinib Counteract Anthracycline Resistance in Cancer Cells Expressing AKR1C32020 | Faculty of Pharmacy in Hradec Králové
- Bruton's Tyrosine Kinase Inhibitor Zanubrutinib Effectively Modulates Cancer Resistance by Inhibiting Anthracycline Metabolism and Efflux2022 | Faculty of Pharmacy in Hradec Králové
- Targeting phosphatidylinositol 3 kinase-beta and -delta for Bruton tyrosine kinase resistance in diffuse large B-cell lymphoma2020 | First Faculty of Medicine
- Rilzabrutinib, an Oral BTK Inhibitor, in Immune Thrombocytopenia2022 | First Faculty of Medicine, Faculty of Medicine in Hradec Králové
- Impaired Toll-like receptor 8-mediated IL-6 and TNF-alpha production in antigen-presenting cells from patients with X-linked agammaglobulinemia +12008 | Second Faculty of Medicine
- Ibrutinib in mantle cell lymphoma: a real-world retrospective multi-center analysis of 77 patients treated in the Czech Republic2023 | First Faculty of Medicine, Faculty of Medicine in Hradec Králové, Third Faculty of Medicine
- Contiguous x-chromosome deletion syndrome encompassing the BTK, TIMM8A, TAF7L, and DRP2 genes2007 | Second Faculty of Medicine
- Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase study2016 | First Faculty of Medicine
- Research Report University Hospital for clinical evaluation of PCI-32765MCL3002Publication without faculty affiliation
- Report of University Hospital Hradec Králové to the clinical trial protocol No: PCYC-1115-CAPublication without faculty affiliation
- Final report of University Hospital Hradec Kralove to the clinical trial protocol no. PCYC-1130-CAPublication without faculty affiliation
- Use of ibrutinib as "bridging" for allogeneic hematopoietic stem cell transplantation from haploidentic donor and subsequent therapy of residual disease after transplantation in a patient with highly adverse mantle cell lymphoma2019 | First Faculty of Medicine
- Dendritic cells in immunopathologyPublication without faculty affiliation
- Severe secondary immune thrombocytopenia in a patient with chronic lymphocytic leukemia2022 | Faculty of Medicine in Hradec Králové, Faculty of Pharmacy in Hradec Králové
- Fixed duration therapy in patients with chronic lymphocytic leukemia2023 | Publication without faculty affiliation
- Chemoimmunotherapy in the First-Line Treatment of Chronic Lymphocytic Leukaemia: Dead Yet, or Alive and Kicking?2021 | Faculty of Medicine in Hradec Králové
- Ibrutinib plus CIT for R/R mature B-NHL in children (SPARKLE trial): initial safety, pharmacokinetics, and efficacy2020 | Second Faculty of Medicine
- Phase 2 study of parsaclisib (INCB050465), a highly selective, next-generation PI3Kδ inhibitor, in relapsed or refractory diffuse large B-cell lymphoma (CITADEL-202)2021 | Faculty of Medicine in Hradec Králové
- Small Molecules in the Treatment of Chronic Lymphocytic Leukemia in 2015 and in the Near Future2015 | First Faculty of Medicine
- Sensitivity to PI3K and AKT inhibitors is mediated by divergent molecular mechanisms in subtypes of DLBCL2017 | First Faculty of Medicine
- COVID-19 in patients with chronic lymphocytic leukemia: a multicenter analysis by the Czech CLL study group2023 | Faculty of Medicine in Hradec Králové, Central Library of Charles University, Faculty of Medicine in Pilsen
- Idelalisib plus rituximab versus ibrutinib in the treatment of relapsed/refractory chronic lymphocytic leukaemia: A real-world analysis from the Chronic Lymphocytic Leukemia Patients Registry (CLLEAR)2023 | First Faculty of Medicine, Faculty of Medicine in Hradec Králové, Third Faculty of Medicine
- A phase 2 study of ibrutinib in combination with bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma2020 | First Faculty of Medicine
- Mantle cell lymphoma: insights into therapeutic targets at the preclinical level2020 | First Faculty of Medicine
- Detailed Functional and Proteomic Characterization of Fludarabine Resistance in Mantle Cell Lymphoma Cells2015 | First Faculty of Medicine
- Therapeutic Approach to Patients with Chronic Lymphocytic Leukemia and Significant Comorbid Conditions2016 | Faculty of Medicine in Hradec Králové
- Modern approach to the treatment of chronic lymphocytic leukemia2023 | Faculty of Medicine in Hradec Králové
- The terapeutic Options for ""Slow- go"" Patients with Chronic Lymphocytic Leukemia2015 | Faculty of Medicine in Hradec Králové